Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy

Key Points

• The study aims to assess how anti-PLA2R antibodies can inform treatment strategies and predict remission in membranous nephropathy.
• Evaluated levels of anti-PLA2R antibodies in patients diagnosed with membranous nephropathy.
• Analyzed therapeutic outcomes and remission rates in relation to antibody levels.
• Utilized statistical analysis to correlate antibody presence with therapeutic effectiveness.
• Higher levels of anti-PLA2R antibodies were linked to lower remission rates.
• Patients with negative anti-PLA2R antibodies showed a significant increase in remission probability (OR 2.5, 95% CI 1.5-3.5, p<0.01).
• Therapeutic strategies adjusted based on antibody levels improved outcomes for patients with membranous nephropathy.